Genes: APP, PSEN1
Mutations: APP KM670/671NL (Swedish), PSEN1: deltaE9
Modification: APP: Transgenic; PSEN1: Transgenic
Disease Relevance: Alzheimer's Disease
Strain Name: B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
Genetic Background: C57BL/6 x C3H)F2
Availability: The Jackson Lab; available through the JAX MMRRC Stock# 034829; Live
These transgenic mice were made by co-injecting two vectors encoding mutant APP and mutant PSEN1. Like the APPSwe/PSEN1dE9 mice generated by crossing transgenic APP animals with those expressing PSEN1dE9, these mice begin to develop Aβ deposits by 6 months of age, with abundant plaques in the hippocampus and cortex by 9 months (Jankowsky et al., 2004). Plaques continue to increase up to around 12 months of age (Garcia-Alloza et al., 2006). Astrocytosis develops in parallel with plaque deposition, with severe gliosis starting around 6 months, especially in the vicinity of plaques. The number of GFAP-positive cells progressively increases with age, with extensive staining throughout the cortex by 15 months (Kamphuis et al., 2012). Tangles are not typical in these animals.
In the B6 congenic line (see related strains below), differences between male and female mice have been reported with regard to the kinetics of plaque deposition in the brain and plasma Aβ levels. In females, levels of Aβ in the plasma increase about 80 percent between the ages of 3 and 15 months, whereas levels reportedly decrease about 40 percent in males over that time, such that by 15 months of age plasma Aβ40 was about fourfold higher in females than in males. A similar trend was seen for Aβ42, although the difference was smaller. In the brain, no sex-related differences in Aβ levels were observed between the ages of 1 and 15 months. In terms of amyloid deposition, males developed plaques more rapidly than females, reaching saturation at 9 months of age, whereas deposition did not plateau in females until around 12 months of age (Ordóñez-Gutiérrez et al., 2015).
The behavior of these mice has been well-characterized. Deficits are seen across multiple cognitive domains, although severity and timing depend on the specific behavioral protocols used (Janus et al., 2015). Contextual memory may be impaired as early as 6 months of age as shown by freezing behavior in fear conditioning tests (Kilgore et al., 2010). Spatial learning is comparable to non-Tg mice at 7 months of age, but impaired by 12 months as measured by performance in the Morris water maze (Lalonde et al., 2005; Volianskis et al., 2010). Spontaneous behavior, such as nest-building and burrowing, is also affected (Janus et al., 2015).
The hybrid line has a relatively high incidence of spontaneous epileptic seizures. Seizures start at a young age and are present in about 65 percent of APPswe/PSEN1dE9 mice by 4½ months of age. Seizures are lethal in only about 5 percent of mice, depending on breeding conditions (Minkeviciene et al., 2009). Other genetic backgrounds, especially the D2 background, are even more prone to seizures (see related strains below).
Deficits in synaptic plasticity have been observed. Specifically, deficits in transient long-term potentiation (t-LTP) have been observed by 3 months, although the degree of impairment is not related to age from 3 to 12 months (Volianskis et al., 2010).
In addition to cognitive, behavioral, and neurological phenotypes, bladder dysfunction has been reported in the B6 congenic line (see related strains below). This phenotype has been observed in both males and females, although with differing ages of onset. Bladder dysfunction was observed in males from a young age, whereas females did not develop the phenotype until around 10 months of age (Ordóñez-Gutiérrez et al., 2014).
This strain does not carry the retinal degeneration allele Pde6brd1.
This model was formerly available through The Jackson Lab as Stock# 004462.
These transgenic mice were made by co-injecting two vectors encoding mutant APP and mutant PSEN1. The APP sequence encodes a chimeric mouse/human APP (Mo/HuAPP695swe) that was “humanized” by modifying three amino acids, and the Swedish mutation was introduced. The PSEN1 sequence encodes human presenilin-1 lacking exon 9 (dE9), which therefore models AD-associated mutations in PSEN1 resulting in exclusion of exon 9, variously known as ΔE9, dE9, deltaE9, Δ9, or delE9. Expression of both genes was directed to the CNS with the mouse prion promoter.
(aka C57BL/6J APPswePsen1de9 and B6.APBTg)
These mice are on a C57 genetic background. They are available as JAX MMRRC Stock# 034832 (formerly available as The Jackson Lab Stock# 005864).
These mice are on a D2 genetic background. They were generated by backcrossing B6.APBTg mice to stock D2 mice (DBA/2J; JAX Stock #000671). Mice on this background are more prone to spontaneous seizures than the B6 congenic. The seizures are lethal, and are thought to account for the premature death of D2.ABPTg mice, 70 percent of which die between 2 and 3 months of age. Those that survive to 6 months of age exhibit reduced amyloid pathology relative to B6 counterparts (Jackson et al., 2015).
When visualized, these models will distributed over a 18 month timeline demarcated at the following intervals: 1mo, 3mo, 6mo, 9mo, 12mo, 15mo, 18mo+.
- Neuronal Loss
- Synaptic Loss
Occasional Aβ deposits can be found by 6 months with abundant plaques in the hippocampus and cortex by 9 months (Jankowsky et al., 2004) and a progressive increase in plaques up to 12 months (Garcia-Alloza et al., 2006).
Minimal astrocytosis at 3 months; significant astrocytosis by 6 months, especially in areas around plaques. Extensive GFAP+ staining at 15 months and later throughout the cortex (Kamphuis et al., 2012).
Changes in LTP/LTD
Transient long term potentiation (t-LTP) is reduced by 3 months. The degree of impairment is not related to age from 3 to 12 months (Volianskis et al., 2008).
Impairment in the Morris water maze at 12 months, specifically during acquisition of the hidden platform sub-task and the probe trial but not in the visible platform test (Lalonde et al., 2005). At 13 months the mice commit more errors in the Morris water maze, but not at 7 months (Volianskis et al., 2008).
Research Models Citations
- Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004 Jan 15;13(2):159-70. Epub 2003 Nov 25 PubMed.
- Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006 Dec;24(3):516-24. Epub 2006 Oct 5 PubMed.
- Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs JA, Jansen AH, Verveer M, de Groot LR, Smith VD, Rangarajan S, Rodríguez JJ, Orre M, Hol EM. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One. 2012;7(8):e42823. Epub 2012 Aug 13 PubMed.
- Ordóñez-Gutiérrez L, Antón M, Wandosell F. Peripheral amyloid levels present gender differences associated with aging in AβPP/PS1 mice. J Alzheimers Dis. 2015;44(4):1063-8. PubMed.
- Janus C, Flores AY, Xu G, Borchelt DR. Behavioral abnormalities in APPSwe/PS1dE9 mouse model of AD-like pathology: comparative analysis across multiple behavioral domains. Neurobiol Aging. 2015 Sep;36(9):2519-32. Epub 2015 May 21 PubMed.
- Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2010 Mar;35(4):870-80. PubMed.
- Lalonde R, Kim HD, Maxwell JA, Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett. 2005 Dec 23;390(2):87-92. PubMed.
- Volianskis A, Køstner R, Mølgaard M, Hass S, Jensen MS. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1δE9-deleted transgenic mice model of ß-amyloidosis. Neurobiol Aging. 2010 Jul;31(7):1173-87. Epub 2008 Sep 13 PubMed.
- Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fülöp L, Penke B, Zilberter Y, Harkany T, Pitkänen A, Tanila H. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009 Mar 18;29(11):3453-62. PubMed.
- Jackson HM, Onos KD, Pepper KW, Graham LC, Akeson EC, Byers C, Reinholdt LG, Frankel WN, Howell GR. DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's disease. PLoS One. 2015;10(5):e0125897. Epub 2015 May 1 PubMed.
- Xiao Z, Cilz NI, Kurada L, Hu B, Yang C, Wada E, Combs CK, Porter JE, Lesage F, Lei S. Activation of neurotensin receptor 1 facilitates neuronal excitability and spatial learning and memory in the entorhinal cortex: beneficial actions in an Alzheimer's disease model. J Neurosci. 2014 May 14;34(20):7027-42. PubMed.
- Maroof N, Ravipati S, Pardon MC, Barrett DA, Kendall DA. Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AβPPswe/PS1ΔE9 mouse model of Alzheimer's disease. J Alzheimers Dis. 2014;42(1):227-45. PubMed.
- François A, Rioux Bilan A, Quellard N, Fernandez B, Janet T, Chassaing D, Paccalin M, Terro F, Page G. Longitudinal follow-up of autophagy and inflammation in brain of APPswePS1dE9 transgenic mice. J Neuroinflammation. 2014 Aug 27;11:139. PubMed.
- Kemppainen S, Hämäläinen E, Miettinen PO, Koistinaho J, Tanila H. Behavioral and neuropathological consequences of transient global ischemia in APP/PS1 Alzheimer model mice. Behav Brain Res. 2014 Dec 15;275:15-26. Epub 2014 Sep 1 PubMed.